How has been the historical performance of Concord Drugs?

Answer:The historical performance of Concord Drugs shows a declining trend in net sales and profits over the past four years.

Breakdown:
Concord Drugs reported net sales of 45.25 Cr for the year ending March 2025, a slight increase from 44.93 Cr in March 2024, but a decrease from 52.09 Cr in March 2023 and 59.06 Cr in March 2022. The total operating income mirrored this trend, remaining at 45.25 Cr in March 2025, compared to 44.93 Cr in the previous year, while it was higher at 52.09 Cr and 59.06 Cr in the earlier years. The total expenditure, excluding depreciation, was 41.11 Cr in March 2025, up from 40.88 Cr in March 2024 but down from 47.50 Cr in March 2023 and 53.37 Cr in March 2022. Operating profit (PBDIT) for March 2025 was 4.14 Cr, slightly up from 4.05 Cr in March 2024, but down from 4.59 Cr and 5.69 Cr in the prior two years. Profit before tax showed a similar decline, reaching 0.69 Cr in March 2025, compared to 0.63 Cr in March 2024, 1.25 Cr in March 2023, and 2.25 Cr in March 2022. Consequently, profit after tax also decreased to 0.34 Cr in March 2025 from 0.47 Cr in March 2024, 0.99 Cr in March 2023, and 1.59 Cr in March 2022. The earnings per share (EPS) reflected this downward trend, with values of 0.34 in March 2025, 0.47 in March 2024, 1.06 in March 2023, and 1.82 in March 2022. Overall, the financial metrics indicate a consistent decline in performance over the four-year period.